A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Phase 2

Completed

• Conditions: Non-Small Cell Lung Cancer
• Interventions: Drug: Gemcitabine; Drug: Cisplatin; Biological: Cetuximab; Biological: IMC-A12 (cixutumumab); Drug: Carboplatin

• Registration Number: NCT00870870
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to determine the number of participants whose cancer shrinks or disappears after treatment on the study.

Detailed Description

Participants with Stage IIIb or IV non-small cell lung cancer (NSCLC) who have not received previous chemotherapy will be stratified, based on disease histology (squamous versus \[vs.\] nonsquamous).

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-03-26
• Study First Submitted QC: 2009-03-26
• Study First Posted: 2009-03-27
• Disposition First Submitted: 2010-09-03
• Disposition First Submitted QC: 2010-09-03
• Disposition First Posted: 2010-09-08
• Primary Completion: 2012-04
• Study Completion: 2012-05
• Results First Submitted: 2018-03-17
• Status Verified: 2018-05
• Results First Submitted QC: 2018-05-01
• Last Update Submitted: 2018-05-01
• Results First Posted: 2018-06-01
• Last Update Posted: 2018-06-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

• Has histologically or cytologically confirmed, Stage IIIb - IV NSCLC
• Has metastatic disease
• Has a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST)
• Has adequate hematologic function
• Has adequate hepatic function
• Has adequate renal function
• Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

Read More

Exclusion Criteria

• Has uncontrolled brain metastases
• Has leptomeningeal disease
• Has received previous chemotherapy for NSCLC (participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)
• Receiving any other investigational agent(s)
• Has a history of treatment with other agents targeting the insulin-like growth factor (IGF) or the epidermal growth factor (EGF) receptor
• Has a known allergy / history of hypersensitivity reaction to any of the treatment components
• Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range [fasting glucose <160 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN) and hemoglobin A1C≤ 7%] and that they are on a stable dietary or therapeutic regimen for this condition
• Has an uncontrolled intercurrent illness
• Pregnant or lactating
• Has a history of another primary cancer, with the exception of: a) curatively resected nonmelanomatous skin cancer; b) curatively treated cervical carcinoma in situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 3 years
• Has superior vena cava syndrome contraindicating hydration
• Has current clinically-relevant coronary artery disease (New York Heart Association III or IV) or uncontrolled congestive heart failure
• Has any National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 3.0 Grade ≥2 peripheral neuropathy
• Has significant third space fluid retention, requiring repeated drainage

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
GCiC (Gemcitabine/Cisplatin/Cetuximab)	Cetuximab	Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)	IMC-A12 (cixutumumab)	Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)	Cetuximab	Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC (Gemcitabine/Cisplatin/Cetuximab)	Cisplatin	Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)	Gemcitabine	Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)	Cisplatin	Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)	Carboplatin	Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC (Gemcitabine/Cisplatin/Cetuximab)	Gemcitabine	Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)
GCiC (Gemcitabine/Cisplatin/Cetuximab)	Carboplatin	Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met \*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]	Randomization to measured progressive disease (PD) (up to 16.9 months)	ORR was defined as the percentage of participants achieving either CR or PR. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST), version (v) 1.0 criteria. CR was defined as the disappearance of all target and non-target lesions and the normalization of the tumour marker level. PR was defined as having at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Percentage of participants is calculated as a total number of participants with CR or PR / total number of participants treated \* 100.

Secondary Outcome Measures

Name	Time	Method
Cmax of Cixutumumab for Cycle 3	Week 7 (Cycle 3, Day 1)
Maximum Concentration (Cmax) of Cixutumumab at Study Day 1	Day 1
Progression-Free Survival (PFS)	Randomization to PD or death due to any cause or censor (up to 16.9 months)	PFS was defined as the duration from the date of randomization until disease progression or death due to any cause, whichever occurred first. Response was defined using RECIST, v 1.0 criteria. PD was defined as having a ≥20% increase in sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants who were alive and without disease progression, PFS was censored at the date of last objective tumor assessment. For participants who did not experience disease progression and were lost to follow-up, PFS was censored at the date of the last objective tumor assessment or the date of last contact.
Duration of Response	Date of first response to the date of PD or death due to any cause or censor ( up to 15.5 months)	The duration of CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of disease progression or death. Response was defined using RECIST v 1.0 criteria. CR was defined as the disappearance of all target lesions and non-target lesions. PR was defined as having at least a 30% decrease in sum of LD of target lesions. Duration of response was censored on the date of last tumor assessment for participants who were alive and have no evidence of disease progression.
Serum Anti-Cixutumumab Antibody Assessment (Immunogenicity)	Prior to first infusions of Cycles 1, 3, and 5 and 30 days following the end of therapy
Cmin of Cixutumumab for Cycle 3	Week 7 (Cycle 3, Day 1)
Overall Survival (OS)	Randomization to death due to any cause or censor (up to 30.4 months)	OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.
Number of Participants With Adverse Events (AEs) or Deaths	Randomization to last dose of study medication (up to 11.7 months) plus 30-day safety follow-up	Data presented are the number of participants who experienced 1 or more AEs, serious AEs (SAEs), and AEs that lead to death during the study including the 30-day follow-up. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this report.
Cmax of Cixutumumab for Cycle 1	Week 1 (Cycle 1, Day 1)
Cmax of Cixutumumab Cycle 5	Week 13 (Cycle 5, Day 1)
Minimum Concentration (Cmin) of Cixutumumab at Study Day 1	Day 1
Cmin of Cixutumumab for Cycle 5	Week 13 (Cycle 5, Day 1)
Time To Progression (TTP)	Randomization to months until PD or censor (up to 16.9 months)	TTP was defined as the duration from the date of randomization until the date of disease progression. Response was defined using RECIST v 1.0 criteria. PD was defined as having a ≥20% increase in the sum of LD of target lesions or the appearance of new lesions and/or unequivocal progression of non-target lesions. For participants without disease progression, TTP was censored at the date of last objective tumor assessment. For participants without disease progression and were subsequently lost to follow-up, TTP was censored at the date of last follow-up visit or at the date of last contact.
Cmin of Cixutumumab for Cycle 1	Week 1 (Cycle 1, Day 1)

Trial Locations

Locations (1)

ImClone Investigational Site; 🇺🇸 Cincinnati, Ohio, United States